A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 791-800

  Kreijtz, Joost H C M ^a   Wiersma, Lidewij C M ^a   De Gruyter, Heidi L M ^a   Vogelzang Van Trierum, Stella E ^a   Van Amerongen, Geert ^b   Stittelaar, Koert J ^b   Fouchier, Ron A M ^e   Osterhaus, Albert D M E ^a   Sutter, Gerd ^c,d   Rimmelzwaan, Guus F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ViroClinics Biosciences   (Netherlands)

^c UNIVERSITY OF MUNICH   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e NONE

Author keywords

Influenza A(H7N9) virus; Modified vaccinia virus Ankara; Vaccine

Indexed keywords

INFLUENZA VACCINE; DRUG CARRIER; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BODY POSTURE; CONTROLLED STUDY; DOMESTIC FERRET; FEMALE; HISTOPATHOLOGY; HYPERPNEA; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A H7N9; INFLUENZA VACCINATION; INTERSTITIAL PNEUMONIA; LETHARGY; LOSS OF APPETITE; LOW DRUG DOSE; LUNG ALVEOLITIS; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIRUS REPLICATION; VIRUS TITRATION; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; FERRET; GENE VECTOR; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); LUNG DISEASES, INTERSTITIAL; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; FERRETS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; LUNG DISEASES, INTERSTITIAL; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS;

EID: 84925757182     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu528     Document Type: Article

References (50)

1. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888-97.
2. Li Q, Zhou L, Zhou M, et al. Preliminary report: epidemiology of the avian influenza A (H7N9) outbreak in China. N Engl J Med 2013;370:520-32.
3. Chen E, Chen Y, Fu L, et al. Human infection with avian influenza A (H7N9) virus re-emerges in China in winter 2013. Euro Surveill 2013;18:1-10.
4. Center of Excellence for Influenza Research and Surveillance (CEIRS) Resources. Cases of H7N9 influenza in China by week of onset (May 16, 2014). < CIDRAP Newsletter.
5. Liu J, Xiao H, Wu Y, et al. H7N9: a low pathogenic avian influenza A virus infecting humans. Curr Opin Virol 2014;5c: 91-7.
6. Van Riel D, Leijten LM, De Graaf M, et al. Novel avian-origin influenza A (H7N9) virus attaches to epithelium in both upper and lower respiratory tract of humans. Am J Pathol 2013;183:1137-43.
7. Kreijtz JH, Kroeze EJ, Stittelaar KJ, et al. Low pathogenic avian influenza A (H7N9) virus causes high mortality in ferrets upon intratracheal challenge: a model to study intervention strategies. Vaccine 2013;31:4995-9.
8. Collin N, De Radigues X, World Health Organization H1N1 Vaccine Task Force. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009;27:5184-6.
9. International Federation of Pharmaceutical Manufacturers and Associations. Authoritative new study reveals global pandemic influenza vaccine capacity [news release]. 23 February 2009. http://www.oliverwyman.com/content/dam/oliver-wyman/global/en/files/archive/pr/OW-HLS-Press-2009-IVC.pdf. Accessed 20 May 2010.
10. Couch RB, Decker WK, Utama B, et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One 2012;7:e50830.
11. De Groot AS, Ardito M, Terry F, et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother 2013;9:950-6.
12. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013;346:f794.
13. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin 2009;5:126-35.
14. Zhang L, Jia N, Li J, et al. Optimal designs of an HA-based DNAvaccine against H7 subtype influenza viruses. Hum Vaccin Immunother 2014;10:1949-58.
15. Chu DH, Sakoda Y, Nishi T, et al. Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9). Vaccine 2014;32:3473-9.
16. Yan J, Villarreal DO, Racine T, et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 2014;32:2833-42.
17. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014;6:234ra55:1-10.
18. Goff PH, Krammer F, Hai R, et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol 2013;87:8235-40.
19. Krammer F, Albrecht RA, Tan GS, et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol 2014;88:3976-85.
20. Klausberger M, Wilde M, Palmberger D, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014;32:355-62.
21. Margine I, Palese P, Krammer F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 2013;81:e51112.
22. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013;369:2564-6.
23. Hahn T, Courbron D, Hamer M, et al. Rapid manufacture and release of a GMP batch of avian influenza A (H7N9) virus-like particle vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. Bioprocessing J 2013;12:4-17.
24. Kreijtz JH, Gilbert SC, Sutter G. Poxvirus vectors. Vaccine 2013;31:4217-9.
25. Moss B. Reflections on the early development of poxvirus vectors. Vaccine 2013;31:4220-2.
26. Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on re-combinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009;8:447-54.
27. Kreijtz JH, Suezer Y, De Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009;199:405-13.
28. Kreijtz JH, Suezer Y, De Mutsert G, et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 2009;4:e7790.
29. Kreijtz JH, Suezer Y, Van Amerongen G, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007;195:1598-606.
30. Veits J, Romer-Oberdorfer A, Helferich D, et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008;26:1688-96.
31. Hessel A, Schwendinger M, Holzer GW, et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 2011;6:e16247.
32. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-40.
33. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immuno-genicity in humans of a novel heterosubtypic influenza Avaccine, MVA-NP+M1. Clin Infect Dis 2011;52:1-7.
34. Hessel A, Savidis-Dacho H, Coulibaly S, et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 2014;9:e88340.
35. Brewoo JN, Powell TD, Jones JC, et al. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 2013;31:1848-55.
36. Kremer M, Volz A, Kreijtz JH, Fux R, Lehmann MH, Sutter G. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol 2012;890:59-92.
37. Wyatt LS, Earl PL, Liu JY, et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004;20:645-53.
38. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 1998;74:57-66.
39. Palmer D, Dowle W, Coleman M, Schild G. Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis. Procedural Guide. Atlanta: US Department of Health, Education, and Welfare, 1975:25-62.
40. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010;50:1487-92.
41. Kreijtz JH, Suzer Y, Bodewes R, et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010;91:2745-52.
42. Van Den Brand JM, Kreijtz JH, Bodewes R, et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadju-vanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 2011;85:2851-8.
43. Bodewes R, Kreijtz JH, Van Amerongen G, et al. Pathogenesis of influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 2011;179:30-6.
44. Schrauwen EJ, Herfst S, Leijten LM, et al. The multibasic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets. J Virol 2012;86:3975-84.
45. Kreijtz JH, Suezer Y, De Mutsert G, et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009;27:6296-9.
46. Richard M, Schrauwen EJ, De Graaf M, et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013;501:560-3.
47. Xu L, Bao L, Deng W, et al. Novel avian-origin human influenza A (H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis 2014;209:551-6.
48. Chen Z, Baz M, Lu J, et al. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014;88:7016-23.
49. Xu Q, Chen Z, Cheng X, Xu L, Jin H. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS One 2013;8:e76884.
50. Keawcharoen J, Spronken MI, Vuong O, et al. Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses. Vaccine 2010;28:5803-9.